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Background: The Rho-associated coiled-coil kinase-2 (ROCK2) is an important signaling transducer in the transmission
of extracellular signals effecting organization of the actin cytoskeleton. ROCK2 has been implicated in numerous
pathologies and the current focus is on understanding the molecular events that couple ROCK2 activity to biological
function. To aid in the search for new ROCK2 substrates, we have developed an analog-sensitive (AS) ROCK2 protein
that allows the use of selective ATP analogs that are not efficiently utilized by other protein kinases.
Results: The analog sensitive protein, M160A ROCK2, was highly active and could phosphorylate proteins from a
cellular homogenate with γ32P-N6 (benzyl)ATP. We show the utility of this approach by identifying a putative ROCK2
substrate, elongation initiation factor-1-α1. We further show that the major site of ROCK2 phosphorylation of EIF1α1
is Thr432.
Conclusions: Our work demonstrates that AS-ROCK2 could be useful in a systematic proteomic approach for identifying
novel ROCK2 substrates.
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The Rho-associated coiled-coil kinase-2 (ROCK2) is a
large serine/threonine kinase that plays diverse roles in
the cell including contraction, motility and morphology
(reviewed in [1]). In the absence of Rho-GTP, ROCK2,
and its closely related homologue ROCK1, adopts an
auto-inhibited form [2], and upon Rho-GTP binding auto-
inhibition is relieved and the kinase adopts an open, active
conformation [3]. Rho-GTP activates ROCK2 to alter the
activity of the actin reorganization machinery. For example,
ROCK2 activation indirectly increases myosin light chain
(MLC) phosphorylation, through the phosphorylation and
inactivation of MLC phosphatase (MLCP) [4]. ROCK2 can
also directly phosphorylate MLC at Ser19 [5], the same site
targeted by MLC kinase. ROCK2 further causes the disrup-
tion of the head-to-tail association of ERM proteins,
through the phosphorylation of ezrin, radixin and moesin* Correspondence: mscheid@yorku.ca
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stated.[6]. In addition, LIM-kinase 2 is activated by ROCK2,
which then phosphorylates its downstream target, cofilin
[7]. Phosphorylation of cofilin inhibits its actin depolymer-
izing function, thus increasing the number of actin fila-
ments and leads to reorganization of the cytoskeleton [8].
Many human cancers demonstrate increased ROCK2
activity, which can augment tumor invasiveness [9,10].
Animal models have revealed that ectopic ROCK2 acti-
vation in established tumors is sufficient to drive metas-
tasis of tumor cells into the surrounding stroma [9].
ROCK2 has also been implicated in the pathogenesis
of hypertension, since ROCKs play a crucial role in
smooth muscle contraction [11], through phosphoryl-
ation of MLC and MLCP. Furthermore, ROCK2 has been
shown to influence the expression of genes that are im-
portant in vascular function, such as plasminogen activa-
tor inhibitor-1 (PAI-1) [12] and osteopontin [13]. Since
ROCK2 plays a role in a number of human diseases, this
kinase has received considerable interest as a potential
therapeutic target.
ROCK2 is a member of the AGC kinase family and
shares homology within the catalytic domain with otherl Ltd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Biotinylated LIMK peptide assay specificity. Serial
dilutions of Phospho-LIMK1 (DRKKRYpTVVGNPY; squares) and LIMK1
(DRKKRYTVVGNPY; circles) peptide with concentrations ranging from
4 μg/ml to 90 ng/ml were bound to streptavidin plates (Pierce) for
2 hours at room temperature (24°C). Wells were then washed and
probed with phospho-LIMK (Cell Signaling) over night at room
temperature. Secondary decoration with IRDye®680 anti-rabbit(Li-Cor)
was performed at room temperature for 1.5 hours. Proteins were
visualized by direct fluorescence scanning with a Li-Cor Odyssey Imager.
Error bars represent the standard deviation of triplicate determinations
and are representative of three independent experiments.
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and SGK. This has led to the realization that ROCK2,
like other AGC kinases, could target sequences that fall
within a characteristic phosphorylation motif of R/KXS/
T or R/KXXS/T [14]. Substrate preference for ROCK2
phosphorylation of this consensus motif is likely gov-
erned by spatial and temporal constraints; for example
PKA distinguishes bona fide substrates through a mech-
anism in which bridging between kinase and substrate is
provided by adapter and scaffold molecules [15].
To identify new ROCK2 substrates, a potentially useful
approach is to modify the kinase so that it utilizes an
ATP molecule restricted from use by other kinases. For
example, an ATP with a bulky hydrophobic group at-
tached to the N6 position of the purine base prevents
entry of the analog into the catalytic site of most protein
kinases [16,17]. The kinase domain can be engineered to
accept this analog by introducing a modification to steric-
ally accommodate the ATP analog. This chemical engin-
eering approach was first demonstrated in the prototypical
protein tyrosine kinase v-Src [17] and has been adapted to
various kinases leading to the discovery of many important
new substrates [18,19].
Here, we have adapted this chemical engineering ap-
proach to ROCK2. We show that a modified ROCK2
harboring a single amino acid substitution in the cata-
lytic domain resulted in a 100-fold decrease in the Km
for N6(Benzyl)ATP utilization compared with wildtype
kinase. Phosphorylation of a cellular homogenate with
γ32P-N6(Benzyl)ATP led to a mixture of highly phosphory-
lated proteins that were separated by 2D-gel electrophor-
esis. Mass spectral identification and biochemical analysis
of one of these phosphorylated proteins, eukaryotic elong-
ation factor-1-α-1 (eEF1α1), demonstrated the utility of
this approach and provides an important reagent for the
future identification of ROCK2 signaling targets.
Results and discussion
Generation of AS-ROCK2
We were interested in identifying ATP binding-pocket
mutations within ROCK2 that permitted the use of
bulky ATP analogs. To screen for these mutations, we
developed an in vitro nonradioactive assay based on
phosphorylation of a biotinylated ROCK2 substrate pep-
tide matching the consensus ROCK2 phosphorylation
site in LIMK. Following phosphorylation in vitro by
ROCK2, the biotinylated LIMK peptides were bound to
a 96 well streptavidin-coated plate and phosphorylation
was measured by probing with a commercially available
phospho-specific antibody coupled to a secondary anti-
body conjugated to an 680 nm wavelength fluorochrome
(IRDye680). Detection of the phospho-peptide antibody
complex was performed directly on-plate using the Licor
Odyssey infrared laser scanner. The assay was simple,rapid, and had a wide dynamic range comparing phospho-
Thr505 LIMK fluorescence with the non-phosphorylated
LIMK peptide (Figure 1). The unphosphorylated peptide
was unreactive to the phosphospecific antibody up to the
maximal concentration tested of 4 μg/ml.
For ROCK2, Met160 is analogous to Ile338 in v-Src
(Figure 2A), where this single bulky residue of v-Src was
shown to prevent the acceptance of N6-modified ATP an-
alogues [20]. Mutation of the Met160 residue in ROCK2 to
an alanine or glycine was modeled to yield the space re-
quired to accommodate N6(Benzyl)ATP. This mutation
was introduced into the W1161A ROCK2 background as
we have previously shown that this protein exhibits high
kinase activity levels [21]. The Met160 to Ala substitution
resulted in a 4-fold increase in substrate phosphorylation
over wildtype ROCK2 at an N6(Benzy)ATP concentration
of 100 μM (Figure 2B). The Met160 to Gly substitution had
a 50% reaction velocity compared with the wildtype se-
quence, while Met135 to Val135 substitution also resulted
in a major decrease in reaction velocity, indicating that
these substitutions are inhibitory.
Since the Met160 mutation resulted in a greater vel-
ocity at 100 μM N6(Benzy)ATP than wildtype ROCK2,
we analyzed this protein over a concentration range of
analog to estimate Km for N6(Benzyl)ATP. We saw no
difference in the Km concentration of ATP between
Figure 2 Creation of AS-ROCK2. A. ROCK2, V-Src, C-Src and rat PKA sequences were aligned using ClustalW. The v-Src ‘gatekeeper’ residue
within the ATP-binding pocket is Ile338 (indicated by arrow) and is primarily responsible for restricting the ability of protein kinases from utilizing
N6-substiuted ATP analogues. Ile338 in v-Src corresponds to Met160 in ROCK2. B. HEK 293 cells were transfected with various FLAG-ROCK2 constructs
where indicated. The following day, cells were lysed and ROCK2 was immunoprecipitated with anti-FLAG conjugated agarose. LIMK peptide was
phosphorylated using N6(Benzyl)ATP, loaded onto streptavidin plates (Pierce), and probed with P-LIMK (Cell Signaling) overnight at room temperature.
Secondary decoration with IRDye® 680 anti-rabbit (Li-Cor) was performed at room temperature for 1.5 hours. LIMK peptide phosphorylation was visualized
by direct fluorescence scanning with a Li-Cor Odyssey Imager. The relative LIMK phosphorylation signal is shown by the histogram for each ROCK2
mutation. Error bars represent standard deviation of triplicate determinations from three independent experiments. Asterisks indicate significant
difference (P < 0.001) with W1161A ROCK2 as using Student’s t-test. C. Kinase activity of W1161A ROCK or W1161A/M160A ROCK2 was determined
as in B, using serial dilutions of ATP with concentrations ranging from 1 mM to 12.8 nM. D. As in C, except N6(Benzyl)ATP was used. For C and D,
error bars represent the range of duplicate determinations. Results are representative of three independent experiments.
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which is similar to the published Km for ROCK2)
(Figure 2C). In contrast, there was a 100-fold decrease
in Km for N6(Benzyl)ATP between the two kinases
(~200 μM for wildtype ROCK2 and ~2 μM for Ala160
ROCK2) (Figure 2D).
eEF1α1 is phosphorylated by AS-ROCK2 in vitro
Next, we utilized M160A/W1161A ROCK2 to phosphor-
ylate HEK293 cellular homogenate. Cellular homogenate
was incubated with M160A/W1161A ROCK2 in thepresence γ32P-N6(Benzyl)ATP (Figure 3A). In addition
to autophosphorylated ROCK2, numerous other 32P-
labeled proteins were clearly observed by autoradiog-
raphy. The phosphorylated protein homogenate was then
fractionated by 2D-electrophoresis and Figure 3B shows
that at least eight proteins were phosphorylated by the
exogenous M160A/W1161A ROCK2 protein. Two spots
in particular were labeled strongly (A and B; Figure 3B),
and one of them (B) was identified by mass spectroscopy
to be the eukaryotic elongation initiation factor-1-α1
(eEF1α1).
Figure 3 Two-Dimensional separation of ROCK2-phosphorylated HEK293 cellular homogenate. A. HEK 293 cells were transfected with
either W1161A or M160A/W1161A ROCK2. The following day, ROCK2 was immunoprecipitated and resuspended in HEK 293 cellular homogenate
(60 μg) with γ32P-N6(Benzyl)ATP in activation buffer for 30 minutes at 30°C. A small sample was taken and separated by SDS-PAGE followed by
staining with Coomassie Blue and exposure to film. B. The remaining sample of M160A/W1161A ROCK2-phosphorylated homogenate was separated
from the beads and proteins were precipitated with acetic acid/TCA, and then resuspended in 2D sample buffer. Proteins were loaded onto pH 3-11NL
or pH 4-7 L IEF strips, as indicated. Following overnight IEF, the samples were separated in the 2nd dimension by 8% SDS-PAGE. Gels were then
silver-stained, dried (upper panel), and exposed to Amersham Hyperfilm (lower panel). Dashed circles indicate putative ROCK2 substrates that
were excised and sent for identification. Results are representative of three independent experiments.
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Thr432) that fell within the ROCK consensus phosphor-
ylation motif. These residues were exchanged for alanine
and subjected to an in vitro kinase assay with W1161A
ROCK2 (Figure 4). Thr432 substitution of eEF1α1 re-
sulted in a 90% loss of phosphorylation, suggesting that
Thr432 is a major site of phosphorylation by ROCK2.The identification of new ROCK2 substrates is import-
ant for understanding how this essential regulator of
cell mobility and contraction signals to control cellular
events. Our study has provided a number of useful ad-
vancements in this regard. First, the biotinylated LIMK
peptide assay was developed to quickly and quantitatively
assess ROCK2 activity in vitro with phospho-specific
Figure 4 Phosphorylation of EF1α1 in vitro by ROCK2. A. EF1α1 (5 μg) was phosphorylated in vitro with W1161A ROCK2 as described in Methods.
The samples were then separated by SDS-PAGE and transferred to a PVDF membrane. FLAG-ROCK2 was visualized by blotting with anti-FLAG M2
antibody, and EF1α1 was detected by anti-EF1α1 antibody. EF1α1 phosphorylation was visualized by phosphoimager. B. Fold increase in phosphorylation
of EF1α1 by W1161A ROCK2 compared with no kinase for each of the Ser/Thr to alanine substitutions. Error bars represent the standard deviation
of triplicate determinations from two independent experiments. C. EF1α1 was phosphorylated in vitro by W1161A ROCK2 in the presence of 10 nm
or 1 μM Y27623. The figure is representative of two experiments.
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LIMK peptide assay could be useful in future research
applications that seek to assess ROCK2 catalytic activity
in vitro, such as testing the catalytic effects of point mu-
tations or the discovery of small compound inhibitors of
ROCK2.
Secondly, we have utilized the biotinylated LIMK pep-
tide assay to evaluate a ROCK2 mutation that allows
utilization of N6(Benzyl)ATP. Since this bulky ATP ana-
log is not efficiently used by ROCK2 (Km of 200 μM;
Figure 2D) or many other protein kinases [17,18], the
M160A ROCK2 protein represents a valuable tool for
the future identification of novel ROCK2 substrates.
This modified protein was able to phosphorylate the
LIMK peptide in vitro, and was able to phosphorylate an
array of proteins in a cellular lysate that could be sepa-
rated by two-dimensional electrophoresis and identi-
fication by mass spectroscopy. This resulted in the
successful identification of the putative ROCK2 substrate
eukaryotic elongation initiation factor-1α-1 (eEF1α1).
The eEF1α1 is a highly conserved GTP-binding protein
that interacts with aminoacyl-tRNA and recruits it tothe ribosome during peptide elongation [22]. In addition
to this role, eEF1α1 has also been found to be a part of a
diverse number of cellular activities, including interac-
tions with actin [23] mitotic apparatus complex forma-
tion [24], association with phosphorylated PKB [25], and
interactions with PDK1 [26].
Izawa and colleagues reported that eEF1α phosphor-
ylation inhibited co-sedimentation with F-actin [27].
eEF1α binds F-actin or aminoacyl-tRNA in a competitive
manner [28]. Thus, eEF1α phosphorylation by ROCK
may release the elongation factor from the cytoskeleton,
allowing binding of aminoacyl-tRNA, leading to local-
ized translation [27]. Other studies have since shown
that overexpression of eEF1α2 leads to filopodia for-
mation in human breast cancer cells, which was re-
versed with the ROCK2 inhibitor Y-27632 [29]. These
results argue that further investigation is required to eluci-
date whether eEF1α1 represents a physiological ROCK2
substrate.
Examination of the eEF1α1 protein sequence re-
vealed that residues Ser53, Thr72, and Thr432 all fall
within a ROCK2 consensus motif R/KXS/T or R/KXXS/T
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tion of these residues to alanine followed by in vitro
phosphorylation by ROCK2 showed that Thr432 is
the major site of ROCK2 phosphorylation, since min-
imal phosphorylation was observed with T432A eEF1α1
(Figure 4). Future work will involve the generation of a
phospho-specific antibody to Thr432 of eEF1α1 that will
aid in elucidating the role of phosphorylation at this
residue in cells.
Amano and colleagues [30] have previously reported
an alternative proteomic approach to identify substrates
of ROCK2, by combining mass spectrometry with affin-
ity column chromatography. This method utilized the
catalytic domain of ROCK2 as bait to probe a fraction of
cytosol for interacting proteins [30], where our ATP
analogue approach relies on a full-length protein that
specifically phosphorylates substrates. Both techniques
are similar in that proteins of interest were first sepa-
rated from non-substrates, followed by identification by
mass spectrometry.
Further identification of ROCK2 substrates using the
ATP analogue approach will focus on specifically enrich-
ing for proteins phosphorylated by the AS-ROCK2 pro-
tein. This could be achieved by utilizing an N6-ATP-γ-S
analogue and substrate enrichment with iodoacetyl-
agarose resin, which binds the sulfonated group [31], prior
to identification by mass spectrometry.
Conclusion
In summary, our work has shown the utility of an AS-
ROCK2 mutation that allows the use of bulky ATP ana-
logs. This model will be of significant value for future
efforts aimed at identifying novel ROCK2 substrates that




HEK (human embryonic kidney)-293 cells were obtained
from the A.T.C.C. (Manassas, VA, U.S.A.) and cultured
in DMEM (Dulbecco’s modified Eagle’s medium) supple-
mented with 10% fetal bovine serum and antibiotics at
37°C in a humidified incubator containing 5% CO2.
Reagents
Antibodies used were anti-FLAG M2 (Sigma-Aldrich),
anti-[phosphoLIMK1(Thr508)/LIMK2(Thr505)] (Cell Sig-
naling Technology) and anti-EF1α1 (H-300) (Santa Cruz
Biotechnology).
Site-directed mutagenesis
The M160A/W1161A and M160G/W1161A ROCK2 were
generated using QuikChange® mutagenesis kit (Stratagene).
Mutations were sequence-verified.cDNA transfections
HEK-293 cells were plated onto 100-mm dishes at 80%
confluence and transfected with 2.5 mg of cDNA using
Lipofectamine™2000 (Invitrogen) following the manufac-
turers protocol. 4 hours post transfection, the medium
was removed and replaced with DMEM containing fetal
bovine serum.
Cell lysis
Cells were lysed in radioimmunoprecipitation (RIPA)
buffer, containing 10 mM sodium phosphate (pH 7.4),
150 mM NaCl, 0.1% (w/v) SDS, 1% (v/v) Triton X100,
0.25% (w/v) deoxycholate, 5 mM EDTA, 25 mM NaF,
25 mM 2-glycerolphosphate, 200 μM Na3VO4 and pro-
tease inhibitors.
Biotinylated LIMK1 peptide assay
FLAG-tagged ROCK2 was immunoprecipitated from
transfected cell lysates with M2 monoclonal antibody
conjugated to agarose (Sigma–Aldrich). Immunopre-
cipitates were washed three times in RIPA buffer,
followed by an additional three times in activation buffer
containing (50 μM Tris–HCl, 0.1 mM EGTA, 0.1% 2-
mercaptoethanol), and finally resuspended in 30 μl of
activation buffer containing various concentrations of
ATP or N6(Benzyl)ATP. Biotinylated (N-terminal) LIMK1
peptide (DRKKRYTVVGNPY) was used as a substrate
(200 μM). Samples were incubated for 30 min at 30°C, the
reaction was terminated by the addition of 7.5 mM EDTA.
The samples were then loaded onto streptavidin plates
(Pierce) and bound for 2 hours at room temperature
(24°C). The plates were then probed with phospho-LIMK
(Cell Signaling) overnight at room temperature. Secondary
decoration with IRDye® 680 anti-rabbit (Li-Cor) was per-
formed at room temperature for 1.5 hours. Proteins were
visualized by direct fluorescence scanning with a Li-Cor
Odyssey Imager.
Cellular homogenate labeling
3 × 106 HEK293 cells were lysed in 2 ml hypotonic lysis
buffer (20 mM Hepes, pH 7.4, 2 mM MgCl2, 200 μM
Na3VO4, 0.25% NP-40, and protease inhibitors). Insol-
uble particulates were removed by centrifugation and
10% glycerol was added to the supernatant and stored
at −80°C. Prior to in vitro labeling, the homogenate was
heat inactivated for 10 min at 60°C. Cellular homogenate
was then added to immunoprecipitated ROCK2 proteins
with γ32P-N6(Benzyl)ATP in activation buffer. The reac-
tion was incubated for 30 min at 30°C and terminated
by the addition of 2X LDS sample buffer.
Two-dimensional electrophoresis
Proteins were precipitated from samples with 4x the vol-
ume acetone, 10% TCA and 20 mM DTT at −20°C for
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4°C for 15 min. The supernatant was removed and the
protein pellet was subjected to an acetone wash, and
then dried of residual acetone under vacuum for 2 min.
The pellet was then resuspended in 260 μl 2D sample
buffer (7 M Urea, 2 M Thio-Urea, 4% CHAPS, 2% DTT,
1% IPG buffer). To ensure protein solubilization, sam-
ples were incubated at room temperature for 15 min
with intermittent vortexing. The sample was then trans-
ferred to a fresh Eppendorf tube and 250 μl was pipetted
into a 13 cm strip holder (GE Healthcare). An immobi-
line dry strip (GE Healthcare) was then placed in the
holder, overlayed with drystrip cover fluid. Both pH 3–
11 NL and pH 4–7 L immobiline dry strips were used,
see figures for details.
Proteins were then separated in the first dimension
with the following isoelectric focusing (IEF) conditions:
10 hours rehydration, 5 hours 30 V, 1 hour 500 V, 1
hour 1000 V, 2.5 hour 8000 V, and 30 min 8000 V for
ph3-11 NL. The conditions for pH 4–7 were as follows:
10 hours rehydration, 5 hours 30 V, 1 hour 500 V, 1
hour 1000 V, 2.5 hours 8000 V, and 0.55 hours 8000 V.
Following IEF, strips were removed from the holders and
pre-equilibrated in SDS-equilibration buffer (50 mM
Tris–HCl, pH 8.8, 6 M Urea, 30% glycerol, 2% SDS, and
10 mg/ml DTT) for 1 hour at room temperature (24°C)
with rocking. Proteins were then separated in the second
dimension with 8% SDS-PAGE. After electrophoresis,
gels were rinsed in ultrapure water and fixed in 50%
ethanol, 10% acetic acid and stained using the Silver
Quest kit (Invitrogen). 32P-labeled proteins identified
by autoradiography were excised from the gel with a
scalpel. Gel fragments were resuspended in 1% acetic
acid in microcentrifuge tubes prior to analysis by mass
spectrometry.
EF1α1 in vitro kinase assay
FLAG-ROCK2 was immunoprecipitated from cell lysates
with 20 μl of M2 FLAG monoclonal antibody conju-
gated to agarose (Sigma-Aldrich). Immunoprecipitates
were washed three times with RIPA buffer, followed by
two additional washes with kinase assay buffer containing
20 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM
dithiothreitol (DTT), and finally resuspended in 30 μl of
kinase assay buffer containing 10 μM ATP and 1 mCi
[32P]ATP. Purified EF1α1 proteins were used as substrate.
Samples were incubated for 30 min at 30°C, and termi-
nated by the addition of 2x LDS sample buffer, and
resolved on 4-12% Criterion™XT precast gel (Bio-Rad
Laboratories). 32P-EF1α1 was visualized by phosphoimager
(Bio-Rad Laboratories).
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